ATE157249T1 - Stickoxide zur gewichtsreduktion - Google Patents

Stickoxide zur gewichtsreduktion

Info

Publication number
ATE157249T1
ATE157249T1 AT91906494T AT91906494T ATE157249T1 AT E157249 T1 ATE157249 T1 AT E157249T1 AT 91906494 T AT91906494 T AT 91906494T AT 91906494 T AT91906494 T AT 91906494T AT E157249 T1 ATE157249 T1 AT E157249T1
Authority
AT
Austria
Prior art keywords
nitrogen oxides
weight reduction
oxazolidine
oxyls
nitroxides
Prior art date
Application number
AT91906494T
Other languages
English (en)
Inventor
James B Mitchell
William G Degraff
Stephen Hahn
Amram Samuni
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE157249T1 publication Critical patent/ATE157249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT91906494T 1990-03-16 1991-03-18 Stickoxide zur gewichtsreduktion ATE157249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49453290A 1990-03-16 1990-03-16

Publications (1)

Publication Number Publication Date
ATE157249T1 true ATE157249T1 (de) 1997-09-15

Family

ID=23964864

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97100145T ATE249829T1 (de) 1990-03-16 1991-03-18 Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress
AT91906494T ATE157249T1 (de) 1990-03-16 1991-03-18 Stickoxide zur gewichtsreduktion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97100145T ATE249829T1 (de) 1990-03-16 1991-03-18 Verwendung von nitroxiden und oxazolidinen zum schutz ionisierender strahlung und oxidativem stress

Country Status (10)

Country Link
US (1) US5462946A (de)
EP (2) EP0787492B1 (de)
JP (1) JP2741427B2 (de)
AT (2) ATE249829T1 (de)
AU (1) AU644865B2 (de)
CA (1) CA2078287C (de)
DE (2) DE69133313T2 (de)
DK (1) DK0787492T3 (de)
ES (1) ES2207690T3 (de)
WO (1) WO1991013619A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714482A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical spin labels and method
US5714510A (en) * 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
US5728714A (en) * 1985-07-18 1998-03-17 Proctor; Peter H. Method for treating hair loss using tempo
US6605619B1 (en) * 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
US5741893A (en) * 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5824781A (en) * 1993-08-16 1998-10-20 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5807831A (en) * 1993-08-16 1998-09-15 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5767089A (en) * 1993-08-16 1998-06-16 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
US5840701A (en) * 1993-08-16 1998-11-24 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5804561A (en) * 1993-08-16 1998-09-08 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5817632A (en) * 1993-08-16 1998-10-06 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5725839A (en) * 1993-08-16 1998-03-10 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules for ERI or MRI
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
AU1837197A (en) * 1996-01-26 1997-08-20 United States of America, represented by the Secretary, Department of Health and Human Services, The National Institutes of Health, The Hydroxylamine compositions for the prevention or retardation of cataracts
WO1997041826A1 (en) * 1996-05-07 1997-11-13 Thomas Jefferson University Use of tempol in the prevention of photoaging
US6096759A (en) 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
JP2002512188A (ja) 1998-04-21 2002-04-23 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 抗酸化剤及び神経保護剤としてのカンナビノイド類
EP1114119A1 (de) 1998-09-09 2001-07-11 Baker Hughes Incorporated Vinylpolymerisationsinhibtor aus gehinderten hydroxylaminen
CA2377621C (en) * 1999-06-23 2009-05-19 Eric F. Bernstein Use of nitroxides in wound healing and in the prevention of photodamage
AU2001293064A1 (en) * 2000-09-26 2002-04-08 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
US20030045461A1 (en) * 2001-09-06 2003-03-06 Jen-Chang Hsia Composition and methods of esterified nitroxides gated with carboxylic acids
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
CN100469776C (zh) * 2002-05-17 2009-03-18 奥特拉控股公司 白内障和其它眼病发展的改善
JP2006501303A (ja) * 2002-10-01 2006-01-12 ミトス・ファーマシューティカルズ・インコーポレーテッド ニトロキシド放射線防護製剤および使用法
JP2006524701A (ja) * 2003-04-25 2006-11-02 ミトス・インコーポレーテッド 酸化防止剤による予防的前処置
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
JP2007500227A (ja) * 2003-05-29 2007-01-11 ミトス・ファーマシューティカルズ・インコーポレーテッド 光増感剤及び音増感剤と関連してのニトロキシドの使用方法
US7977366B2 (en) * 2003-10-14 2011-07-12 Cornell Research Foundation, Inc. Treating an inflammatory disorder or inhibiting respiratory burst in adherent neutrophils with chemical inhibitors of neutrophil activation
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
AU2004293105B2 (en) 2003-11-20 2010-09-09 Othera Holding, Inc. Amelioration of macular degeneration and other ophthalmic diseases
US20090209581A1 (en) * 2005-02-02 2009-08-20 Louis Habash Nitroxides for use in treating or preventing immunological diseases
WO2006084199A2 (en) * 2005-02-02 2006-08-10 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing amyloid-related diseases
JP2008528694A (ja) 2005-02-02 2008-07-31 ミトス・ファーマシューティカルズ・インコーポレーテッド 糖尿病の治療または予防において使用するためのニトロキシド類
WO2006127592A2 (en) * 2005-05-26 2006-11-30 Othera Pharmaceuticals, Inc. Use of hydroxylamine derivates for inhibiting vitrectomy-induced cataracts
WO2007021847A2 (en) * 2005-08-11 2007-02-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for determining redox status of a tissue
WO2007025244A2 (en) 2005-08-25 2007-03-01 Houle Philip R Treatment systems for delivery of sensitizer solutions
US7538130B2 (en) * 2005-09-26 2009-05-26 Basf Corporation Hindered amine light stabilizer, methods of making, and compositions
US20070160642A1 (en) * 2006-01-12 2007-07-12 Pacetti Stephen D Implantable medical devices coated with a polymer-bound superoxide dismutase mimic
US20070197599A1 (en) * 2006-02-02 2007-08-23 Matier William L Hydroxylamines and derivatives as anti-angiogenic agents
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20070197593A1 (en) * 2006-02-22 2007-08-23 Matier William L Hydroxylamines and derivatives for treatment of inflammatory conditions of the liver
WO2008013660A2 (en) 2006-07-07 2008-01-31 Biostratum, Inc. Inhibitors of advanced glycation end products
WO2008067417A2 (en) * 2006-11-29 2008-06-05 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating or preventing hypercholesterolemia
WO2008101195A2 (en) * 2007-02-16 2008-08-21 Othera Holding, Inc. Drug resistance reversal in neoplastic disease
EP2120943A2 (de) * 2007-03-09 2009-11-25 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Nitroxidradikal als behandlung für neurodegeneration
US7820963B2 (en) * 2007-08-06 2010-10-26 Metabolic Alayses, Inc. Method for generation and use of isotopic patterns in mass spectral data of simple organisms
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
US8859235B2 (en) 2009-08-14 2014-10-14 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US20110130421A1 (en) * 2009-10-29 2011-06-02 Georgetown University Methods and Compositions for the Treatment of Chronic Renal Hypertension
WO2012110435A1 (en) * 2011-02-14 2012-08-23 Basf Se Bio process additives
US20130224281A1 (en) * 2011-04-07 2013-08-29 United States Of America As Represented By The Administrator Of The National Aeronautics & Space Method and composition for ameliorating the effects for a subject exposed to radiation or other sources of oxidative stress
WO2015139034A1 (en) * 2014-03-14 2015-09-17 The General Hospital Corporation System and method for imaging free radicals
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
CA3097468A1 (en) 2018-04-16 2019-10-24 S&R Farmaceutici S.P.A. Mixture of resveratrol supported on metal hydroxide and non-supported pure resveratrol for treating female fertility
CN114502546A (zh) 2019-08-01 2022-05-13 普拉特戈公司 晚期糖基化终产物的抑制剂
US12208089B2 (en) 2021-05-25 2025-01-28 Louis Habash Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005044A1 (en) * 1986-12-29 1988-07-14 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals

Also Published As

Publication number Publication date
CA2078287C (en) 1996-11-26
EP0520005A1 (de) 1992-12-30
ES2207690T3 (es) 2004-06-01
AU644865B2 (en) 1993-12-23
EP0520005A4 (en) 1993-04-21
JPH05501114A (ja) 1993-03-04
CA2078287A1 (en) 1991-09-17
WO1991013619A1 (en) 1991-09-19
DE69127437T2 (de) 1998-02-05
EP0787492B1 (de) 2003-09-17
DE69133313T2 (de) 2004-07-01
EP0520005B1 (de) 1997-08-27
AU7542391A (en) 1991-10-10
US5462946A (en) 1995-10-31
DK0787492T3 (da) 2004-02-02
DE69127437D1 (de) 1997-10-02
DE69133313D1 (de) 2003-10-23
JP2741427B2 (ja) 1998-04-15
EP0787492A1 (de) 1997-08-06
ATE249829T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
DE69127437D1 (de) Stickoxide zur gewichtsreduktion
DE69223157D1 (de) Sauerstoff-substituierte derivate von nucleophil-stickstoffoxid-addukten und ihre verwendung als stickstoffoxid-donor-prodrugs
DE68926095D1 (de) Vorwärtsgekoppelter linearer Verstärker
FI924624A7 (fi) Laite vedyn ja hapen uudestaanyhdistämiseksi ja laitteen käyttö
FI930455A7 (fi) Yhdisteitä ja menetelmiä geeniekspression inhiboimiseksi
NO922818D0 (no) Fremgangsmaate for ombrekking av strukturerte dokumenter
FI935540A0 (fi) Filtersammansaettning med ett filterelement och en taettningsanordning
DE69233269D1 (de) Gas-sterilisierung
IT1244790B (it) Cassetto smontabile ed amovibile atto ad un facile trasporto
DE69120351D1 (de) Vorwärtsgekoppelter Verstärker
DE69133084D1 (de) Schutzüberzug und verwendung desselben
FI931406A0 (fi) Foerfarande foer framstaellning av lineariskt polyeten med laog taethet
FI920564A7 (fi) Heterosyklisiä typpiyhdisteitä
FI941968A0 (fi) Rengas- ja hihnakoostumuksia
IT1212088B (it) Derivati piperazinici ad attivita'anticolinergica e/o antiistaminica.
NO894845L (no) Fremgangsmaate og materialer for mikrobiell bioomdannelse av toluen og andre fenylforbindelser.
DK0642506T3 (da) Heterocyclisk disubstituerede sulfonaminocarbonylforbindelser
NO171798C (no) Fremgangsmaate for behandling av sinkholdige biprodukter og avfallsmaterialer
NO921834L (no) Smerteregulerende sammensetning og fremgangsmaate for fremstilling
NO920930D0 (no) Innretning for varmebehandling av en endeloes bane
DE69107214D1 (de) Laser und verstärker.
FI933939A0 (fi) Foerfarande och anordning foer identifiering och avlaegsnande av upphoejningar i materialbanor
DE69227053D1 (de) Heterocyclische Verbindungen und deren Herstellung
DE69306136D1 (de) Transistorfolgeverstärker
NO930358D0 (no) Forbindelser og fremgagsmaater for inhibering av genekspresjon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties